Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
110.54 -0.32 (-0.29%) 04/21/25 [NYSE]
101.00 x 1 115.98 x 1
Realtime by (Cboe BZX)
101.00 x 1 115.98 x 1
Realtime 110.54 unch (unch) 16:00 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
110.02
Day High
111.64
Open 110.87
Previous Close 110.86 110.86
Volume 1,094,676 1,094,676
Avg Vol 2,556,520 2,556,520
Stochastic %K 77.96% 77.96%
Weighted Alpha +11.02 +11.02
5-Day Change +3.02 (+2.81%) +3.02 (+2.81%)
52-Week Range 94.72 - 120.92 94.72 - 120.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 226,597,840
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 51,722 M
  • Annual Income, $ 11,941 M
  • EBIT $ 14,544 M
  • EBITDA $ 20,658 M
  • 60-Month Beta 0.56
  • Price/Sales 4.45
  • Price/Cash Flow 10.24
  • Price/Book 5.08

Options Overview Details

View History
  • Implied Volatility 27.24% ( +0.34%)
  • Historical Volatility 30.12%
  • IV Percentile 96%
  • IV Rank 47.60%
  • IV High 43.36% on 04/08/25
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 2,318
  • Volume Avg (30-Day) 2,440
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 47,658
  • Open Int (30-Day) 59,446

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.12
  • Number of Estimates 3
  • High Estimate 2.24
  • Low Estimate 1.98
  • Prior Year 1.80
  • Growth Rate Est. (year over year) +17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.71 +13.12%
on 04/09/25
Period Open: 112.13
114.44 -3.41%
on 04/03/25
-1.59 (-1.42%)
since 03/21/25
3-Month
97.71 +13.12%
on 04/09/25
Period Open: 99.73
116.91 -5.45%
on 03/10/25
+10.81 (+10.84%)
since 01/21/25
52-Week
94.72 +16.70%
on 04/22/24
Period Open: 94.36
120.92 -8.58%
on 08/30/24
+16.18 (+17.15%)
since 04/19/24

Most Recent Stories

More News
Housing Figures in Picture for Next Week

U.S. Monday Economic Lookahead U.S. leading economic indicators (March) Featured Earnings ...

MEDP : 288.99 (-2.46%)
AON : 355.95 (-3.12%)
GOOGL : 147.67 (-2.31%)
AGNC : 8.16 (-2.16%)
WRB : 67.33 (-2.14%)
HCA : 317.61 (-5.19%)
NVS : 110.54 (-0.29%)
ABBV : 170.16 (-1.64%)
TMUS : 253.48 (-3.27%)
TSLA : 227.50 (-5.75%)
T : 26.33 (-3.02%)
IBM : 236.22 (-1.08%)
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly...

AZN : 66.90 (-1.02%)
NVS : 110.54 (-0.29%)
AMGN : 273.68 (-1.30%)
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival...

ONCY : 0.5750 (+2.50%)
URGN : 9.66 (-0.10%)
NVS : 110.54 (-0.29%)
PHIO : 2.83 (+3.66%)
ONC.TO : 0.79 (+2.60%)
HURA : 4.20 (+1.20%)
Fabhalta® (iptacopan capsules), first oral treatment for adult patients with PNH, now available in Canada

Fabhalta is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH),1,2 a chronic, rare and...

RY : 115.21 (-0.89%)
NVS : 110.54 (-0.29%)
RY.TO : 159.38 (-0.95%)
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

For Immediate ReleasesChicago, IL – April 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

AZN : 66.90 (-1.02%)
NVS : 110.54 (-0.29%)
ABBV : 170.16 (-1.64%)
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo partnered,...

AZN : 66.90 (-1.02%)
NVS : 110.54 (-0.29%)
ABBV : 170.16 (-1.64%)
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the expanded...

AZN : 66.90 (-1.02%)
JNJ : 156.92 (-0.35%)
NVS : 110.54 (-0.29%)
PFE : 22.04 (-0.45%)
SNY : 50.93 (+0.06%)
FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...

BAYRY : 5.9100 (-1.83%)
NVS : 110.54 (-0.29%)
GILD : 104.33 (-0.20%)
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small...

AZN : 66.90 (-1.02%)
JNJ : 156.92 (-0.35%)
NVS : 110.54 (-0.29%)
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator

Baskin-Robbins has nothing on Vanguard. The ice cream chain is famous for offering 31 flavors to ice cream lovers. Meanwhile, Vanguard's family of exchange-traded funds (ETFs) features 90 choices for investors....

^MKRUSDT : 1,344.942 (+0.19%)
VEA : 50.51 (-0.47%)
SAP : 250.54 (-2.67%)
VOO : 472.37 (-2.38%)
VYMI : 72.76 (-0.32%)
NVS : 110.54 (-0.29%)
VGK : 69.46 (-0.67%)
^MKRBTC : 0.015400 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 113.07
2nd Resistance Point 112.35
1st Resistance Point 111.45
Last Price 110.54
1st Support Level 109.83
2nd Support Level 109.11
3rd Support Level 108.21

See More

52-Week High 120.92
Fibonacci 61.8% 110.91
Last Price 110.54
Fibonacci 50% 107.82
Fibonacci 38.2% 104.73
52-Week Low 94.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro